$1.91
+0.06 (+3.24%)
Open$1.90
Previous Close$1.85
Day High$1.94
Day Low$1.85
52W High$3.56
52W Low$1.25
Volume—
Avg Volume283.8K
Market Cap79.18M
P/E Ratio—
EPS$-2.00
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,130.9% upside
Current
$1.91
$1.91
Target
$42.61
$42.61
$22.54
$42.61 avg
$49.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.49M | 26.17M | 29.17M |
| Net Income | -6,413,122 | -6,638,758 | -7,979,028 |
| Profit Margin | -23.3% | -25.4% | -27.4% |
| EBITDA | -10,041,478 | -10,799,684 | -11,152,703 |
| Free Cash Flow | -6,132,912 | -6,792,749 | -5,207,622 |
| Rev Growth | +12.4% | +6.3% | +17.3% |
| Debt/Equity | 0.29 | 0.25 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |